WallStSmart
ZNTL

Zentalis Pharmaceuticals Llc

NASDAQ: ZNTL · HEALTHCARE · BIOTECHNOLOGY

$2.06
+4.04% today

Updated 2026-10-28

Market cap
$194.28M
P/E ratio
—
P/S ratio
4.42x
EPS (TTM)
$-1.96
Dividend yield
—
52W range
$1 – $7
Volume
1.2M

Zentalis Pharmaceuticals Llc (ZNTL) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-24.25M$-39.14M$-86.83M$-154.09M$-163.75M$-207.82M$-170.86M$-125.25M
Capital expenditures$227000.00$352000.00$758000.00$6.11M$2.55M$583000.00$221000.00$0.00
Depreciation$51000.00$111000.00$160000.00$544000.00$1.43M$1.39M$1.29M—
Stock-based comp$308000.00$617000.00$23.15M$35.74M$46.84M$54.82M$67.27M$20.72M
Free cash flow$-24.48M$-39.49M$-87.58M$-160.20M$-166.30M$-208.41M$-171.08M$-125.25M
Investing cash flow$-227000.00$-352000.00$-284.83M$-18.11M$-114.18M$-44.46M$176.56M—
Financing cash flow$9.47M$81.83M$360.44M$178.52M$261.04M$237.30M$108000.00—
Dividends paid————————
Share repurchases————————
Debt repayment————————
Net change in cash——$-11.22M$6.31M$-16.89M———

Frequently asked questions

What is Zentalis Pharmaceuticals Llc's revenue?

Zentalis Pharmaceuticals Llc's trailing twelve-month revenue is $26.86M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does ZNTL generate?

ZNTL produced $-125.25M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ZNTL's balance sheet healthy?

ZNTL holds $35.99M in cash and equivalents against — in long-term debt, on $216.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.